News round-up for 16-20 September by DDW Senior Digital Content Editor Diana Spencer.

This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies.

The top stories:

Study shows low rates of T-cell malignancies following CAR-T

A new study has demonstrated that the frequency of second primary malignancies (SPMs) is no higher with CAR-T cell therapies than with previous standard-of-care strategies.

Positive early data for Alzheimer’s natural killer cell therapy

NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD).

Cell therapy developer ArsenalBio raises $325 million

Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours.

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1.

New data support CAR-T therapy in neuroinflammatory diseases

Kyverna Therapeutics has revealed continued positive results for its CAR-T therapy KYV-101 in B cell-driven autoimmune diseases.